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Abstract: Allogeneic hematopoietic cell transplantation (allo-HCT), a treatment option in 
hematologic malignancies and bone marrow failure syndromes, is frequently complicated by 
Graft-versus-host disease (GVHD). The primary treatment for GVHD involves immune 
suppression by glucocorticoids. However, patients are often refractory to the steroid therapy, 
and this results in a poor prognosis. Therefore alternative therapies are needed to treat 
GVHD. Here, we review data supporting the clinical investigation of a novel cellular therapy 
using Wharton’s jelly (WJ)-derived mesenchymal stromal cells (MSCs) as a potentially safe 
and effective therapeutic strategy in the management of GVHD. Adult-derived sources of 
MSCs have demonstrated signals of efficacy in the management of GVHD. However, there 
are limitations, including: limited proliferation capacity; heterogeneity of cell sources; 
lengthy expansion time to clinical dose; expansion failure in vitro; and a painful, invasive, 
isolation procedure for the donor. Therefore, alternative MSC sources for cellular therapy 
are sought. The reviewed data suggests MSCs derived from WJ may be a safe and effective 
cellular therapy for GVHD. Laboratories investigated and defined the immune properties of 
WJ-MSCs for potential use in cellular therapy. These cells represent a more uniform cell 
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population than bone marrow-derived MSCs, displaying robust immunosuppressive 
properties and lacking significant immunogenicity. They can be collected safely and 
painlessly from individuals at birth, rapidly expanded and stored cryogenically for later 
clinical use. Additionally, data we reviewed suggested licensing MSCs (activating MSCs by 
exposure to cytokines) to enhance effectiveness in treating GVHD. Therefore, WJCs should 
be tested as a second generation, relatively homogeneous allogeneic cell therapy for the 
treatment of GVHD. 
Keywords: allo-HCT; GVHD; WJ-MSCs 
 
1. Introduction: Allogeneic Hematopoietic Cell Transplantation and Acute Graft-versus-Host 
Disease 
Allogeneic hematopoietic cell transplantations (allo-HCT) are increasingly used as a treatment for 
management of hematologic malignancies, bone marrow failure syndromes, and inborn errors of 
metabolism [1]. They are often complicated by graft-versus-host disease (GVHD), a common cause of 
non-relapse morbidity and mortality. The curative potential for allo-HCT, when applied as a therapy in 
the management of hematologic malignancies, specifically derives from an immunologically driven, 
graft-versus-tumor effect mediated principally by donor T cells, and associated with a lesser risk for 
relapse when compared to high-dose chemo-radio therapy and autologous HCT. Donor-derived T cells 
are also responsible for mediating the occurrence of GVHD, a common transplant-related complication 
affecting a significant percentage of patients undergoing allo-HCT [2–4]. Second only to relapse of the 
primary disease for which the transplant was employed as a cause of morbidity and mortality following 
allo-HCT, GVHD represents the major non-relapse barrier to the success of this otherwise potentially 
curative treatment [2]. 
GVHD can be classified as an acute (aGVHD) or chronic (cGVHD) clinical syndrome. Both have 
distinct clinical manifestations, natural histories, treatment responses and prognoses, although overlapping 
presentations are relatively common [5,6]. Acute GVHD manifests commonly as an acute inflammatory 
process primarily involving the integument, intestinal tract, liver, and frequently presents as a maculopapular 
rash, nausea, vomiting, diarrhea and hepatic cholestasis. In contrast, the cGVHD’s inflammation leads 
to fibrosis of involved organs and frequently presents clinically with sicca syndrome-like features, 
scleradermatous-like skin changes, cytopenias, and chronic fibrosing pulmonary, hepatic and intestinal 
manifestations. The severity of aGVHD can be determined by a staging/grading system [7]. Patients 
with aGVHD grades I−II experience five-year leukemia-free survival of 44%–51%; in contrast, survival 
decreases to 26% for patients with grade III and 7% for grade IV aGVHD [8]. The severity of chronic 
GVHD historically could be determined as either limited or extensive, although recently a classification 
schema has improved prognostication and treatment response determinations [9]. 
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2. Current Risk Factors and Disadvantages with Graft-versus-Host Disease (GVHD) 
Chronic GVHD associates with a decreased risk of relapse of hematologic malignancies after  
allo-HCT. However, it continues to represent the leading cause of late treatment-related deaths among 
allo-HCT recipients. GVHD commonly targets the thymus, resulting in distortion and disruption of 
normal thymic architecture, thereby leading to defective thymopoiesis. Both acute and chronic forms 
impact thymic recovery after allo-HCT, and this associates with reduction in naïve T cells and T-cell 
receptor excision circles (TRECs), which results in a narrow T-cell repertoire. This fact, in conjunction 
with a necessary escalation in the immunosuppressive drugs used to treat GVHD, results in increased 
systemic infections and significant associated morbidity and mortality [10–12]. 
The risk factors associated with the development and severity of GVHD include human leukocyte 
antigen (HLA) mismatching between donor and recipient, sex mismatching, advanced recipient and/or 
donor age, stem-cell source, and methodology of GVHD prophylaxis [13,14]. GVHD commonly occurs 
in patients undergoing HLA-matched sibling and unrelated donor transplants. This mismatching likely 
can be attributed to donor-recipient mismatches for minor histocompatibility antigens not currently 
accounted for in routine HLA typing [15,16]. 
Importantly, the majority of patients that allo-HCT could benefit does not have an HLA-matched 
sibling donor. This problem was addressed by developing registries for HLA-matched unrelated donors, 
which facilitated access to allogeneic stem-cell transplantation for many patients. However, significant 
under-representation for many ethnic groups exists in current registries [17]. Therefore, alternate graft 
sources have increasingly been utilized. For patients who lack HLA-identical siblings or unrelated 
donors, development of novel therapeutic strategies has led to remarkable growth in the use of HLA 
mismatched unrelated adult and cord blood stem cell sources, as well as haploidentical related donors. 
The increased use of alternative donor stem cells in allo-HCT accompanies an increased risk for 
transplant-related complications and requires more effective prophylactic and treatment strategies [18]. 
Currently, prophylactic strategies are most effective at contending with the risk of acute and chronic 
GVHD. Although many prophylactic strategies have been studied, the most commonly employed are 
optimal HLA matching at MHC class I and II loci between donor and recipient, pharmacologic 
approaches that are employed to block T-cell antigen recognition and resultant proliferation during the 
early initiating phases of aGVHD. The most commonly employed pharmacologic strategies consist of a 
calcineurin inhibitor in combination with methotrexate or mycophenolate mofetil and an mechanistic 
target of rapamycin (MTOR) inhibitor such as rapamycin [19]. Approaches that are less common, but 
increasingly in use, include graft manipulation through in vivo or ex vivo T-cell depletion strategies and 
limiting tissue damage caused by the preparative regimen through the employment of less intensive, yet 
adequately immunosuppressive chemo-radiation regimens. Despite these prophylactic measures, often 
inflammatory cascades are triggered and donor T cells begin destroying host tissues. 
The standard initial treatment for both acute and chronic GVHD is steroid-based therapy. 
Unfortunately, significant percentages of patients become resistant to steroid therapy and subsequently 
must be treated with second-line immunosuppressive agents [5,6]. Steroid-refractory aGVHD portends 
a poor prognosis; second-line agents frequently prove ineffective and, as a result, survival is <10% at 
five years. Therefore, alternative therapies are needed to treat GVHD following allo-HCT, particularly 
in the setting of steroid-resistant disease. 
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3. Advantages of Bone Marrow-Derived Mesenchymal Stromal Cells (MSCs) as Cellular 
Therapy for Acute Graft-versus-Host Disease (aGHVD) 
Many immunosuppressive strategies have been studied for steroid-refractory aGVHD, though none 
have proven to be consistently effective and safe for this clinical problem. Promising treatments for 
steroid-refractory aGVHD involve the infusion of third-party, HLA-disparate, unrelated bone marrow 
derived mesenchymal stromal cells (BM-MSC). The in vivo and in vitro properties of BM-MSC  
suggest their potential use in a broad range of inflammatory and immune-mediated conditions, such as 
GVHD. BM-MSC are a population of undifferentiated multipotent mesenchymal stromal cells which 
express HLA class I and do not express HLA class II or costimulatory molecules CD40, CD80 or  
CD86 [20–23]. BM-MSC have been demonstrated to modulate immune and inflammatory responses in 
animal models of inflammatory disease including GVHD [24–28], and to facilitate repair of connective 
tissues [29–32]. 
MSCs inhibit T cells that have been induced by a variety of stimuli from activating and  
proliferating [23,33]. They also down-regulate inflammatory cytokine expression such as tumor necrosis 
factor (TNF)-α, IL2R-α, elafin, and interferon-γ (IFN-γ) [34,35]. Dander et al. investigated the effects 
of MSC infusion on lymphocyte counts in transplanted patients with steroid-refractory GVHD [35]. 
They found CD4+ T cell subsets changed significantly after MSC infusion and significant improvement 
in patient symptoms was associated with an increase in Tregs increased and decrease in Th1 and Th17  
Le Blanc et al. [36] reported the first case of successful treatment for severe refractory aGVHD using  
ex vivo expanded haploidentical MSCs. Their subsequent report demonstrated a positive therapeutic 
effect using allogeneic MSCs in patients experiencing steroid-refractory aGVHD with no significant 
adverse events attributed to the cells [37]. 
After the initial reports of safety and tolerance, additional studies reported encouraging clinical results 
and confirmed the safety of MSCs in the treatment of steroid-refractory aGVHD [36–58].  
Illustrative demonstrations for efficacy and safety have been reported to date by multiple investigators. 
Kurtzberg et al. reported [59] that using allogeneic MSCs as a rescue agent for severe treatment-resistant 
aGVHD demonstrated a 64% response rate in 59 children by day 28, and the response to MSCs 
correlated with improved overall survival at 100 days [45]. This work suggests an excellent risk/benefit 
profile for MSC therapy [45,60]. Martin et al. reported a randomized, placebo-controlled, multi-center 
phase III trial of MSCs in the treatment of steroid-refractory aGVHD involving 244 patients [48]. 
Although the endpoint of durable complete response >28 days was not significantly better in the  
MSC-treated population, significant differences in response for patients with multi-organ involvement, 
liver and intestinal involvement were found for the MSC-treated cohort. 
Table 1 summarizes the published reports describing the clinical outcomes for patients treated with 
MSCs in the management of both aGVHD and cGVHD [36–58]. These reports included patients that 
received a variety of conditioning regimens including myeloablative, or non-myeloablative, or reduced 
intensity conditioning (RIC), with no apparent differences in the response to MSC treatment. 
Furthermore, patients included in these reports received MSCs from many sources including  
HLA-identical, haploidentical, or third party, unrelated and unmatched donors. The majority of clinical 
data reported used BM-MSCs; however, other sources of MSCs have been studied. Fang et al. used 
MSCs derived from adipose tissue [40–42], with no apparent differences in response or safety compared 
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to BM-MSCs. Important for the availability of off-the-shelf cell therapy, MSCs from freshly expanded 
samples or from cryogenically stored/thawed cell preparations have been used as well, with no apparent 
differences in response [61]. MSCs have been shown to be safe: no ectopic tissue formation has been 
derived from infused MSCs in animal models or human studies. [62,63]. Finally, MSCs caused no harm: 
no clearly defined increased incidence of opportunistic infections or relapse of malignancy have been 
reported to date [64]. In summary, the data support the concept of MSCs as a safe, well-tolerated and 
variably effective treatment for GVHD. Importantly, MSCs can be cryogenically banked, thawed and 
given without the need for donor-recipient HLA-matching. 
4. Limitations of Bone Marrow-Derived MSCs as a Cellular Therapy for aGVHD 
There are specific problems that limit BM-MSCs usefulness. The isolation requires aspiration from 
the marrow cavity which is a painful, invasive procedure, with certain risks. Several studies demonstrate 
a limited expansion potential or slower expansion for adult-derived MSCs in vitro compared to fetal  
tissue-derived MSCs. Furthermore, adult MSCs may be less-responsive than fetal or neonatal MSCs in 
certain applications [65–70]. Therefore, alternative tissue sources, such as discarded tissues resulting 
from pregnancy, containing fetal-derived MSCs have been considered as an alternative MSC source. 
Recently, an exploratory clinical study using fetal-derived MSCs was reported demonstrating feasibility, 
safety and efficacy [56]. This review focuses on two areas related to the potential for these tissues, with 
the aim to improve the next iteration of clinical trials. First, we review the literature suggesting that 
MSCs from discarded fetal tissues might offer certain advantages over BM-MSCs for GVHD therapy. 
This idea relates to BM-MSCs’ aforementioned limitations that may be overcome using an alternative 
MSC source. Second, we reviewed literature suggesting in vitro conditioning by cytokine exposure, 
called “licensing,” of MSCs during expansion could improve their clinical effect in GVHD. This subject 
relates to the relative plasticity of MSCs to culture conditions such as hypoxia, cytokine exposure, etc., 
that changes the MSC physiology and may improve their clinical effect. Lastly, we review MSCs’ impact 
on immunophysiology during GVHD. We theorize that MSCs derived from the umbilical cord may be 
an effective alternate source for MSCs, which are safely and painlessly collected to replace BM-MSC, 
for GVHD prevention or treatment. 
5. Possible Advantages of Umbilical Cord-Derived MSCs 
The stroma of umbilical cord, also known as Wharton’s jelly (WJ, or WJCs below), is a source of 
primitive, loose connective tissue that is rich in hyaluronan. WJ supports and cushions the umbilical 
vessels. WJ contains an MSC population. The population of MSC in WJ has certain advantages to other 
MSC sources (see Table 2). For example, it is easily, safely and painlessly harvested following birth 
from the discarded umbilical cord after the umbilical cord blood has been collected. WJCs grow more 
quickly and produce more cells during expansion in vitro compared with BM-MSCs [71,72] and they have 
immune properties similar to adult-derived MSCs from bone marrow and adipose tissue [68,71,73–75]. 
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Table 1. GVHD patients treated with MSCs. 
Citation 
MSC 
Source 
MSC Donor No. of Patients/GVHD Grade HCT Conditioning 
Dose of 
MSCs (/kg) 
Effect on GVHD Ref. 
LeBlanc, K. et 
al., 2004 
BM Haploidentical (mother) 1 (9 yr boy) Grade 4 Myeloablative 
2 × 106 first;  
1 × 106 
second 
Improvements 33 
Ringden, O. et 
al., 2006 
BM 
HLA identical sib n = 2; 
Haploidentical n = 6;  
HLA mismatch n = 4 
9 (12 infusions);  
steroid refractory; aGVHD 8;  
cGVHD 1 
Myeloablative n = 5;  
RIC n = 3;  
ATG only n = 4 
0.6–9 × 106 
Complete response 6;  
Response 1;  
Slight effect 1;  
No response 4 
34 
Fang, B. et al. 
2006, 2006, 
2007, 2009 
Adipose 
MSC 
Unrelated mismatch; 
Haploidnetical; 
Haploidentical;  
Unrelated mismatch n = 4 
1 (38 yr);  
2 steroid refractory;  
1 chronic hepatic;  
6-steroid refractory aGVHD 
Myeloablative 
2 × 106 first;  
1 × 106 
second 
Complete response;  
Complete response;  
Complete response;  
Complete response;  
5/6 complete response 
37–40 
Muller, I. et al., 
2008 
BM 
Mismatch family n = 8;  
HLA identical n = 2;  
HLA matched unrelated n = 1 
7 (11 infusions);  
aGVHD n = 2;  
cGVHD n = 3;  
Hemophagocytosis n = 1;  
Graft rejection prophylaxis n = 1 
Myeloablative n = 5; 
RIC n = 2 
0.4–3 × 106 
aGVHD 1/2 alive and well; cGVHD 
1/3 slide improvement; 
Hemophagocytosis, good response;  
Graft rejection prophylaxis alive  
and well 
46 
LeBlanc, K.  
et al., 2008 
BM 
HLA identical sib n = 5; 
Haploidentical n = 18;  
Unrelated mismatch n = 69 
55 (92 infusions); Grade 2 n = 5; 
Grade 3 n = 25Grade 4 n = 25 
Unknown 0.4–9 × 106 
Children 17/25 complete response, 
4/25 partial response 
Adult 13/30 complete response, 5/30 
partial response; 
total 30/55 complete response (54%), 
partial response 9/55 (16%) 
Overall 2 yr survival 53% for 
complete response vs 16% for partial 
or non-response 
43 
von Bonin, M. 
et al., 2008 
BM Unrelated mismatched 
13 (32 infusions) 
Grade 3 n = 2 
Grade 4 n = 11 
Myeloablative n = 1 
RIC n = 12 
0.6 × 106 
(0.6–1.1) 
2 patients (15%) complete response 
5/11 (45%) partial response 
47 
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Table 1. Cont. 
Citation MSC 
Source MSC Donor 
No. of Patients/GVHD 
Grade HCT Conditioning Dose of MSCs (/ kg) Effect on GVHD Ref. 
Zhou, H. et al., 
2009 
BM 
HLA matched,  
unrelated 
4 cGVHD 
Nonmyeloablative  
n = 4 
1–2 × 107 
(4 to 8 infusions) 
4/4 Complete response 49 
Kebriaei, P.  
et al., 2009 
BM 
Osiris 
unrelated 
unmatched n = 6 
31 (62 infusions) 
Grade 2 n = 21 
Grade 3 n = 7 
Grade 4 n = 3 
Myeloablative n = 15 
RIC n = 8 
Nonmyloablative n = 4 
DLI n = 4 
2 × 106 n = 16 
8 × 106 n = 15 
24/31 Complete response, 5 partial 
response 
2 No response 
41 
Arima, N. et al., 
2010 
BM 
Related, HLA 
identical n = 1 
Unknown 
3 
Grade 3 n = 3 
RIC n = 1 
unknown n = 2 
0.5–2 × 106 
intra-arterial injection  
into GVHD sites 
1/3 partial response 35 
Baron F. et al., 
2010 
BM 
third party, 
mismatch 
20 patients 
(19 historic controls) 
Nonmyeloablative, 
coinfusion w/ MSC 
n = 20 
Unknown 
MSC coinfusion appears safe 
MSC coninfusion might prevent 
death from GVHD without impacting 
GVT 
36 
Lucchini, G.  
et al., 2010 
BM 
Single donor 
unrelated HLA 
mismatch 
aGVHD Grade 1–4 
or cGVHD n = 11 
Variable: TBI, RIC, 
etc. 
0.7–3.7 × 106 
1–5 infusions 
8/11 Complete (23%) or partical (47%) 
response 
3 No response 
44 
Weng, J.Y.  
et al., 2010 
BM 
HLA matched 
third party, 
mismatched 
cGVHD 
73% severe, 26% 
moderate) 
n = 19 
Variable: TBI, RIC, 
etc. 
0.23–1.42 × 106 
1–5 infusions 
14/19 Complete (4) or partial (10) 
response 
5 Died 
48 
Sanchez-Guijo, 
F. et al., 2014 
BM 
Unknown, 
Assume unrelated 
mismatch 
aGVHD Grade 2–4 
n = 25 
unknown 
0.7–1.31 × 106 
4 infusions 
17/24 responded 
11/17 complete and 6/17 partial 
7/24 no response 
54 
Introna, M.  
et al., 2014 
BM 
Unrelated third 
party 
GVHD, n = 40: 15 
children, 25 adults 
Variable: 
myeloablative, RIC 
1.5 × 106 
(0.8–3.1 × 106) 
Median of 3 infusions 
(range 2–7 infusions) 
27/40 responded, 11/40 complete, 16/40 
partial. Children and adults responded at 
same rate. 
18 Died 
51 
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Table 1. Cont. 
Citation MSC 
Source MSC Donor 
No. of 
Patients/GVHD 
Grade 
HCT Conditioning Dose of MSCs (/ kg) Effect on GVHD Ref. 
Resnick, I.B. 
et al., 2013 
BM 
Third party fully 
mismatched (62), third 
party haploidentical (5) 
aGVHD, grade 2–4, 
n = 50 
Myeloablative (45), RIC (5); 
TBI (13) and fludarabine (32) 
1.14 × 106 
(0.3–4.27 range) 
Range of 1–4 
infusions per patient 
17/50 complete, 33/50 
partial response. 
5 Died 
52 
Ball, L.M.  
et al., 2013 
BM Unrelated third party 
aGVHD, grade 3–4, 
n = 37 children, 
median age 7 
Variable: 9 TBI, 28 
chemotherapy-based 
1–2 × 106 
Median of 2 infusions 
(range 1–13 
infusions) 
24/37 complete, 13/37 
partial, 5 no response 
50 
Ringden, O.  
et al., 2013 
Fetal 
membrane 
cells 
Unrelated third party 
aGVHD,grade 3–4, 
n = 9 
Chemotherapy, or 
chemotherapy and TBI 
0.9–2.8 × 106 
2/8 complete, 4/8 partial, 3 
no response 
53 
Wu, K.H.  
et al., 2011 
UC-MSC Unrelated third party 
aGVHD, grade 3–4, 
n = 2 
Chemotherapy, or 
chemotherapy and TBI 
3.3–8.0 × 106 
1–3 infusions 
2/2 complete 55 
Prasad, V.K. 
et al., 2011 
BM       
Kurtzberg, J. 
et al., 2014 
BM 
Unrelated third party 
(Osiris) 
aGVHD, grade 3–4, 
n = 12 
11 myeloablative, 1 RIC 
8 × 106, Median of 8 
infusion (2–21 range) 
7/12 complete, 2/12 partial, 
9/12 complete resolution of 
GI problems 
42 
Martin, P.J.  
et al. 2010 
BM 
Unrelated third party 
(Osiris) 
GHVD, grades B–D, 
n = 244 
unknown 2 × 106, 8 infusions 
76% complete or partial 
response at 100 day, most 
effective for GI and liver 
45 
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Table 2. Comparison of WJ- MSC features with other MSCs. 
 WJ-MSCs BM-MSCs AD-MSCS 
Collection Non-Invasive Invasive Invasive 
Induced Pain No Pain Painful Procedure Minimum to Moderate 
Risk of Collection No Risk Moderate Minimum to Moderate 
Source Fetal Origin Adult Origin Adult Origin 
In vitro Expansion High Expansion Moderate Expansion Moderate Expansion 
In vitro Growth Faster Growth Slower Growth Faster Growth 
6. Attractiveness of MSCs 
The immune properties of MSCs make them attractive for immunological disorders. These immune 
properties are: (1) low immunogenicity and naïve MSCs do not strongly stimulate allogeneic  
T-lymphocyte proliferation; (2) MSCs suppress the proliferation of activated T lymphocytes; (3) increased 
production of regulatory T cells; and (4) a shift in the immune response towards tolerance or anergy 
since MSCs do not stimulate B cells and prevent B cells from becoming stimulated. 
7. Mechanisms for MSC Immune Suppression 
The mechanisms of MSC immune suppression have been reviewed elsewhere (see [34,76,77]). 
GVHD may be modeled in vitro since treatments that impact the inflammatory response are reflected by 
assays of the suppression of mitogen-activated or allo-antigen-activated T-cell proliferation, as well as 
the expansion of regulatory T cells, which would reflect a critical component of tolerance induction. The 
mechanisms used by MSCs are under debate. Evidence exists to support both a direct, contact-dependent 
mechanism that is mediated at least in part by MSC expression of the cell death ligand, B7-H1 [78], and 
an indirect, non-contact dependent mechanism mediated by various cytokines and growth factors such 
as prostaglandin E2 (PGE2), cyclooxygenase (COX) 1 and 2, hepatocyte growth factor (HGF), 
transforming growth factor-β, interleukin 10, human leukocyte antigens G5 and E, leukemia inhibitor 
factor, indoleamine 2,3-dioxygenase (IDO), and others [33,34,74,76,77,79–81]. With regards to the 
direct mechanism, recent work indicates that a transfer of cytosolic contents from MSCs to other cells may 
mediate part of the MSC’s regenerative effects. This connection has also referred to as nanotubes [82,83]. 
As seen below, the mechanisms are not fully determined and the literature is filled with examples and 
counterexamples. 
8. Comparison of MSC Immune Properties 
Several studies compared the immune properties of BM-MSCs, WJCs and MSCs derived from 
adipose tissues [68,71,73,74,84,85]. Najar et al. reported that adipose-derived MSCs and WJCs had 
similar in vitro immunosuppressive effects for lymphocyte proliferation, compared to BM-MSCs: MSCs 
target CD4+ and CD8+ T cells for immune suppression equally; adipose-derived and WJCs inhibit  
T-cell activation; and MSCs were immunosuppressive regardless of the type of stimuli used to activate 
the lymphocytes [85]. MSC immune suppression was mediated by COX 1 and 2 enzymes and by the 
production of PGE2 and did not involve HGF. In agreement with Najar et al.’s findings, Chen et al. 
found that PGE2 synthesis, mediated by COX2, produces the majority of WJCs’ suppressive effects on 
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T-cell proliferation and on IFN-γ secretion [65]. PGE2 expression by WJCs was stimulated by 
inflammatory signals IFN-γ or interleukin-1β produced by peripheral blood mononuclear cells following 
mitogen or allogeneic stimulation. Critically, they found that WJCs cultured with unstimulated (naïve) 
T cells do not secrete much PGE2; however, following co-culture with stimulated T cells, WJCs excreted 
more PGE2. 
9. MSC Stimulation and Expression 
MSCs have little effect on unstimulated T cells, and exposure to activated T cells or inflammatory 
cytokines changes MSCs so they display immunosuppressive behavior [28,68,71,74,78,86,87]. This has 
been termed “licensing” or “priming” of MSCs. Chen et al. found that indoleamine 2,3-dioxygenase 
(IDO) and transforming growth factor beta (TGF-β) played little role in MSC’s suppression of the  
T-cell proliferation. As a counterexample to Chen et al.’s finding that IDO had little role. Yoo et al.  
had diametrically different findings when they compared the immunoregulatory properties of  
adipose-derived, umbilical cord blood-derived MSCs, WJCs and BM-MSC [68]. They found that MSCs 
from all four tissue sources responded to either IFN-γ or tumor necrosis factor-α (TNF-α) secreted from 
activated T cells by inducing IDO secretion, and the released IDO from MSCs suppressed T-cell 
proliferation, and led to decreases in TNF-α and IFN-γ. Yoo et al. reported that, while MSCs responded 
to IFN-γ or TNF-α exposure to upregulate IDO expression, they did not increase expression of HGF, 
Cox 1 and 2, interleukin-10, and TGF-β. Prasanna et al. also examined the immune properties of MSCs 
from BM and WJ, in addition to the effect of IFN-γ and TNF-α exposure on these properties [74]. They 
found that IFN-γ or TNF-α stimulation produced subtly different responses between BM-MSCs and 
WJCs. For example, IFN-γ or TNF-α exposure increased the expression of the immune-adhesive ligand, 
CD54, in both BM-MSCs and WJCs. However, IFN-γ increased expression of HLA class 2 in  
BM-MSCs and not in WJCs. Prasanna et al. also reported that IFN-γ exposure did not strongly affect 
the immunogenicity of MSCs in their in vitro T-cell proliferation assays [74]. In contrast to these 
findings, Cho et al. reported that IFN-γ exposure induced expression of MHC class II in swine and 
human WJCs, and that IFN-γ stimulated WJCS produced an antibody response following subcutaneous 
or intravenous injection of allogeneic WJCs faster than when unlicensed WJCs were used in a swine 
model [86]. One unexpected finding in the Prasanna et al. report was the importance of MSC 
proliferation (possibly) on immune-suppressive properties: both BM-MSCs and WJCs that had been 
mitotically inactivated lost their immune suppressive effect. To our knowledge, this was the first report 
to correlate MSC proliferation with suppression of lymphocyte proliferation. The mechanism that makes 
cells with higher mitotitic index more immune suppressive is unknown. If MSC proliferation is critical 
for immune modulation, this would significantly impact upon how MSCs are derived for therapeutic use. 
The differences between Cho et al. and Prasanna et al. on changes in HLA expression are explained 
by work from Deuse et al., who compared the immunogenicity of allogeneic BM-MSCs and WJCs both 
in vitro and in vivo following exposure to different doses of IFN-γ [71]. At doses of IFN-γ below  
50 ng/mL, IFN-γ upregulated HLA-DR and doses from 100–500 ng/mL of IFN-γ downregulated  
HLA-DR. Interestingly, in all cases, WJCs had lower expression of HLA-I and HLA-DR compared to 
BM-MSCs, WJCs had weaker allogeneic T-cell stimulation compared to BM-MSCs, and WJCs had 
longer survival following allogeneic transplantation in immunocompetent Balb/c mice. 
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10. MSCs Synthesize Anti-Inflammatory Protein Galectin 
Using reverse transcriptase PCR, galectins (Gal) 1, 3, 8 and 9 have recently been identified as being 
produced by MSCs [88]. Gal-1 was identified as the initial lectin to be involved in the process of  
MSC-mediated suppression of allo-reactive T cells [89]. Knockdown of Gal-3 demonstrated that Gal-3 
also plays a role in MSCs’ immunosuppressive effects on T cells [90]. The secretion of Gal-3 into the 
media is sufficient to cause inhibition of T-cell expansion [88]. Since Gal-3 and Gal-1 both demonstrate 
immunosuppressive potential, these galectins have been proposed as in vitro biomarkers for MSC 
immunomodulatory potency [88,89,91]. 
11. MSCs Synthesize Anti-Inflammatory Protein Tumor Necrosis Factor-α-Stimulated Gene 6 
(TSG-6) 
MSCs have been demonstrated to secrete tumor necrosis factor-α-stimulated gene 6 (TSG-6) when 
exposed to inflammatory stimuli [92]. TSG-6 is a hyaluronan receptor (CD44)-binding protein that 
inhibits TNF-α and neutrophil accumulation, and thus blocks inflammatory tissue damage [93,94]. Work 
from Dr. Prockop’s lab indicates that MSC homing to sites of injury is unnecessary for the MSCs’ 
therapeutic effect. For example, MSCs reduce inflammatory damage without homing to the site of 
damage (e.g., while MSCs are trapped in lungs following IV infusion) via MSC-secreted TSG-6 [95–97]. 
This leads to healing in corneal models, recovery of damaged tissue, and prevents allogeneic corneal 
transplantation rejection [96,98]. In diabetic models, TSG-6 was shown to inhibit Th1 responses 
preventing pre-diabetic mice from becoming fully diabetic [94]. In neuro-inflammation and traumatic 
brain injury models, the anti-inflammatory effects from MSCs by TSG-6 were mediated by downstream 
signaling through nuclear factor-kB and mitogen-activated protein kinases (MAPK) [99,100]. 
Importantly, MSCs do not need to be given at the site of injury; i.v. administration was effective and 
TSG-6 by itself could duplicate the effects of MSCs [94,97,98,100]. Dr. Prockop’s lab described novel 
3D culture conditions that enhance MSC anti-inflammatory properties via enhanced TSG-6 and PGE2 
release [92,101]. 
12. Microvesicles 
As reviewed [102–107], microvesicles or a subset of microvesicles called exosomes mediate some of 
the therapeutic effects of MSCs. MSCs release factors into the medium, such as TSG-6, which have  
anti-inflammatory properties and which account for MSC’s paracrine effects [104,108]. Others have 
indicated that microvesicles alone are not as effective as the cellular counterpart, suggesting direct 
contact is important for immune modulation [109]. MSC microvesicles have been suggested as a therapy 
for GVHD [110]. Since MSCs are amenable to targeted modifications that may optimize them as 
microvesicle-delivery vehicles [106], the future may offer customized MSC-derived microvesicle 
formulations for off-the-shelf use for GVHD, myocardial infarction or cancer therapy from the spent 
medium of bioreactors [106,111]. 
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13. Dendritic Cells 
Since we wrote the previous review on this subject [112], the effect of MSCs on dendritic cells (DC) 
has been better defined. The consensus was that MSCs prevent DC maturation and inhibit cytokine 
production by DCs [77]. In 2011, Chiesa et al. showed that following intravenous injection of MSCs, 
DCs stop migrating to peripheral lymph nodes within 20 minutes of infusion [113]. DC activation was 
prevented, and by preventing migration to lymph nodes, there was a deficit in antigen presentation and 
CD4+ T cell production. Since this effect was observed 20 min after infusion, a circulating factor made 
by MSCs is likely responsible, possibly TSG-6 or galectin (discussed below). In addition to loss of 
antigen presentation by DCs, less IL-2 and TNF-α was observed, but no differences in IFN-γ production. 
Importantly, priming of MSCs by LPS exposure enhanced the effect (the inhibition of DC migration and 
activation). The impairment of DC migration and activation resulted in an inhibition of pathogenic 
antigen-specific T cells. 
It has been shown repeatedly that MSCs limit the proliferation of stimulated CD4+ lymphocytes.  
In vitro, human MSCs impair expansion of stimulated CD4+ and CD8+ and impair IFN-γ synthesis by 
activate CD4+ and CD8+ cells [114]. Taken together, these findings support the observed 
immunomodulation effect of human MSCs in a xenogenic LPS-induced lung injury murine model which 
included enhanced survival, reduced pro-inflammatory mediators TNF-α, IL-1β, etc. [115]. 
Separation of GVHD and GVL: Recent work from Li et al. showed that chemokine receptor 7 (CCR7) 
was important for guiding MSCs to secondary lymphoid organs [116]. By enhancing migration of MSCs 
to secondary lymphoid organs, MSCs may enhance immune tolerance (reducing GVHD) while maintaining 
the GVL effect, although this has yet to be demonstrated clinically. As noted above, MSC infusion may 
prevent DC migration to peripheral lymph nodes [113] and thus slow DC-mediated T-cell expansion. 
To summarize, MSCs from Wharton’s jelly, adipose tissue and bone marrow can potently suppress 
T-cell activation, and suppress both CD4+ and CD8+ T-cell proliferation induced by mitogen or 
allogeneic stimulation. Both soluble factors and direct contact are important for full effect of MSCs on 
immune cells. These studies did not consistently identify soluble factors involved; rather, they indicate 
a role for PGE2, IDO, COX 1 and 2, and other factors. The reason for these differences is unknown. 
Several studies indicate that differences exist between MSC sources, but the physiology that accounts 
for these differences is not currently understood. For example, does MSC proliferation or some other 
attribute limit MSC immune suppression [74]? MSCs from adipose, BM and WJ have similar in vitro 
and in vivo immune properties. The advantages of WJCs, e.g.; their lower immunogenicity, less immune 
activation and slower rejection compared to BM-MSCs, would not be apparent without direct 
comparisons (as was conducted in these studies). While some studies found that WJCs and adipose 
MSCs have equal or superior suppression of activated T-cell proliferation compared to BM-MSCs, in 
other studies the differences were less apparent. Finally, consistently, adipose and Wharton’s jelly MSCs 
have superior in vitro expansion properties compared to BM-MSCs. 
14. Priming MSCs: Modification of MSC Properties for Regenerative Medicine 
As mentioned above, MSCs’ immune properties—specifically their immunogenicity, ability to 
suppress T-cell activation, and immune suppression of activated T-cell and B-cell proliferation, can be 
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licensed or primed. This suggests that the therapeutic effect of MSCs may be “tuned” to improve 
performance for a particular application. Several studies that address this hypothesis are discussed briefly 
below [28,74,78,86,87]. Cho et al. showed that exposure of WJCs to IFN-γ increases the expression of 
MHC class I and induces the expression of MHC class II [86]. This was accompanied by increases in 
the immunogenicity of WJCs in an allogeneic swine model. Similar and different findings were reported 
by Prasanna et al., as was discussed above [74]. Again, the theme is that IFN-γ exposure modifies MSC 
effect on immune properties including expression of IDO, HLA class I and class II surface marker 
expression, etc. Tipnis et al. reported that IFN-γ caused WJCs to upregulate the expression of cell death 
ligand B7-H1, in addition to confirming that IFN-γ stimulates increased expression of IDO, and induces 
HLA class II expression [78]. Valencic et al. evaluated two variables: the priming effect of IFN-γ 
exposure on WJCs and the timing of lymphocyte exposure to WJCs [87]. They found that the timing of 
WJC priming was critical to reveal their immune suppressive effects on lymphocytes, and priming WJCs 
increased their immune suppressive action in both contact and non-contact settings. In contrast,  
if pre-stimulated lymphocytes were added to non-primed WJCs, the lymphocytes showed normal or 
enhanced proliferation. Deuse et al. examined the dose-dependent effects of IFN-γ on BM-MSCs and 
WJCs and found that higher levels of IFN-γ stimulation produce a stronger effect of WJCs on immune 
suppression [71]. 
The in vitro work suggests that primed MSCs would be more effective at treating chronic GVHD, 
where they are placed into an environment which will rapidly license them to begin immune suppression, 
which fits with animal model and human clinical observations [28,46]. It also suggests that un-primed 
MSCs given together with hematopoietic stem cells during allo-HCT would be ineffective at preventing 
GVHD, which again is supported by animal GVHD model work by Polchert et al. [28]. Moreover, such 
speculation might be retrospectively confirmed from clinical data. Additionally, the in vitro work 
suggests that IFN-γ-priming would improve MSCs’ therapeutic effect when given together with 
hematopoietic stem cells before GVHD has developed; this has been confirmed in a GVHD  
mouse model [28]. 
While Polchert’s work fits with in vitro work that indicates that IFN-γ priming will have beneficial 
effects in GVHD, primed MSCs have not yet been tested in clinical use. Currently, there is no reason to 
believe that primed MSCs would not be safe and effective for clinical use. In fact, the in vitro and animal 
model data suggest the primed MSCs would have more potent therapeutic effect than naïve MSCs. We 
further speculate that hindsight will clarify the target tissue effects reported for MSCs in GVHD [48] 
once the interactions of MSCs with Tregs, Th1, Th17 and Th2-cell subsets are resolved. 
The issues with MSCs as a cellular therapy are the following: First, there remains concern about 
characterization of MSCs as a result of the ISCT consensus definition statement [117]. Efforts are 
underway to develop more refined methods for MSC characterization, production, and bioassays which 
would enable MSC optimization and clinical translation [114,118–122]. Second, MSCs are a heterogeneous 
population (discussed in [119]). Lacking standardized manufacturing methods and consensus on the 
identity of MSC subpopulations, identification of clinically relevant cells and optimization of clinical 
products is a concern. Third, it is assumed that there will be variability between samples that may result 
from differences between donors, e.g.; physiological differences, health status, donor age or sex. 
Additionally, MSCs may be isolated from different tissues from the same donor. These potentially 
confounding variables should be considered when developing reference materials [119]. Fourth, there is 
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no uniform in vitro bioassay for MSC immune modulation to correlate with clinical response [114]. 
Thus, while human MSCs can be tested in vitro, or in xenogenic bioassays, no correlation between 
performance in vitro and clinical effect in vivo is established. These challenges exist for MSCs, but they 
have not posed a significant barrier for clinical testing: In CellTrials info blog site, Alexey Bersenev 
identified 90 MSC trials underway in 2013 worldwide and 1894 clinical trials are recruiting patients 
(found using the single search parameter: MSCs on the clinicaltrials.gov site 12 October 2014) [123]. 
15. Identification of MSC Stem Cell Subsets 
As reviewed [124], nestin-positive cells have been shown as prospective markers for native MSC in 
mouse. Recently, PDGFR-α and CD51 have been identified as co-localizing on nestin-positive human 
MSCs [125]. These findings suggest a consistent theme across species and may enable follow up studies 
to confirm whether native human MSCs can be prospectively isolated and whether tissue-specific 
differences in native MSC populations exist. Others have suggested that clonal subsets of CD271+ cells 
contain most of the MSC CFU-F and may serve as an enriched population of native MSCs for clinical 
application [126]. Since we do not yet have an understanding of the in vitro expansion conditions needed 
to select and maintain native MSC populations, they have not been functionally characterized in terms 
of immune modulation properties. 
16. Manufacturing MSCs for GVHD Treatment 
In our previous review of this subject, we discussed licensing MSCs by INF-γ exposure to potentially 
improve their potency for GVHD [28,127]. Since then, MSCs have been shown to be even more plastic 
in their immune functions. For example, MSCs express toll-like receptors (TLR) 2, 3 and 4 [128–130]. 
Waterman et al. [130] neatly demonstrated two sharply contrasting MSC immune phenotypes that they 
called MSC type 1 and MSC type 2. MSC type 1 were primed using the specific TLR4 agonist LPS, and 
MSC type 2 were primed or licensed by the TLR3 agonist, poly (I:C). Stimulation by TLR4 resulted in 
the secretion of more pro-inflammatory factors, such as IL6, IL8, IL10, and TLR3-priming resulted in 
secretion of factors that were mostly immune suppressive, such as IL1RA, RANTES (CCL5), IP10 
(CCL10) [130]. This observation fits with observations by Mastri et al. [131], who observed increased 
expression of IL6, IL10, IL11, HGF, LIF and TNF-α by MSCs after TLR3 priming using poly(I:C) and 
enhance therapeutic potency for cardiac repair. TLR activation of MSCs and IFN-γ priming of MSCs 
are likely needed to fully express the immune suppressive capabilities of MSCs. In summary, MSC 
potency as immune modulatory cells depends upon priming, and individual MSC clonal lines may use 
different modulation mechanisms [126]. In addition, it is likely that the expansion medium used for 
MSCs may impact their immune physiology [132] and tissue source of the MSC does, too [85,133,134]. 
17. Conclusions 
In summary, MSCs appear to be safe and well-tolerated, and they offer a hope for treatment of  
steroid-refractory GVHD patients. The clinical outcomes reported to date have been encouraging; 
however, there is ample room for improvement. Most clinical trials have used BM-MSCs; adipose-
derived MSCs were used in a few trials for GVHD, and WJCs have been tested clinically for GVHD in 
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only two reported patients [58]. As discussed above, in vitro testing of MSCs suggests that off-the-shelf, 
unmatched cryopreserved MSCs derived from WJ may be a second generation of MSC-based cell 
therapy for GVHD. Finally, we must expand our understanding of the concept of priming MSCs since 
it improves effectiveness in an animal GVHD model and in pertinent in vitro assays. New information 
about MSC biology should be translated rapidly to clinical evaluation for safety and efficacy for therapy 
in steroid-resistant GVHD. Indeed, our center will soon begin enrollment of patients on a phase I clinical 
trial of ex vivo expanded WJCs in steroid-refractory aGVHD. 
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